Clinical Trial

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the pathologic complete response rate at cystectomy in patients after being treated with a combination therapy of atezolizumab, platinum, and etoposide.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-03-28; most recent amendment 2026-06-23.
Status change: Not Yet Recruiting → Recruiting 2022-06-27
Trial Details
NCT Number NCT05312671
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Genentech, Inc.
Conditions Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
Enrollment 63 participants
Start Date 2022-06-27
Primary Completion 2027-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-25